Commonwealth Equity Services’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Commonwealth Equity Services’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10,317	Closed	-$194K	–	2749
2018 Q4	$194K	Sell	10,317 -4,168	-29%	-$86.9K	﹤0.01%	2344
2018 Q3	$359K	Sell	14,485 -11,564	-44%	-$284K	﹤0.01%	2027
2018 Q2	$629K	Buy	26,049 +4,472	+21%	+$121K	﹤0.01%	1595
2018 Q1	$626K	Buy	+21,577	New	+$612K	﹤0.01%	1559

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commonwealth Equity Services's CNCR Position: Q1 2019 in Review

Commonwealth Equity Services sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q1 2019, closing a stake of 10,317 shares — an estimated $194K sold.

Commonwealth Equity Services first reported a position in CNCR in Q1 2018 and held it in 4 quarters. The position peaked at $629K in Q2 2018. 21 funds tracked by Wall St. Rank hold CNCR as of Q1 2019.

Commonwealth Equity Services reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q1 2019 after selling out during the quarter.
Commonwealth Equity Services sold 10,317 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q1 2019, an estimated $194K.
Commonwealth Equity Services first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q1 2018 and held it in 4 quarters.
Commonwealth Equity Services's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $629K in Q2 2018.
21 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q1 2019.

Based on Commonwealth Equity Services's 13F filing for Q1 2019, filed 13 May 2019.